Imagion Biosystems Limited has lodged Appendix 3X, Final Director’s Interest Notice, with the Australian Securities Exchange.
View the Final Director’s Interest Notice.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal